Demonstrating broad immune response

Inovio is achieving a growing body of human data from multiple clinical studies that is demonstrating the broad immune stimulating characteristics of our SynCon® vaccine platform and providing evidence of the potential to provide preventive and/or therapeutic capabilities in different disease areas:

  • Unprecedented antigen-specific, dose-related T-cell immune responses reported in cancer and HIV:
  • Unprecedented antigen-specific, dose-related T-cell immune responses reported in cancer and HIV:

    • In a Phase I study of VGX-3100, this therapeutic vaccine for cervical dysplasia drove robust immune responses to antigens from high risk types of human papillomavirus (HPV) infection and these immune responses displayed a powerful killing effect on cells changed by HPV into precancerous dysplasias. 78% of patients showed T-cell responses in the validated ELISpot assay (83%, or 5 of 6 patients, in the highest dose group). Further tests measured the ability of CD8+ T-cells from vaccinated patients to kill cells displaying HPV antigens on their surface: 91% of patients who developed T-cell responses showed the presence of CD8+ "killer T-cells.” These killer T-cells are believed to be critical for the treatment of cervical dysplasia and ultimately cancer caused by HPV as well as for potentially treating other cancers and infectious diseases.

    • Phase I study of PENNVAX®-B , our vaccine for clade B HIV (prevalent in North America and Europe). In this study of uninfected subjects, T-cell responses (CD4+, CD8+, or both) were observed to at least one of the vaccine antigens in 88.9% (24 of 27) of evaluated subjects after three vaccinations with PENNVAX®-B and our IL-12 cytokine gene adjuvant followed by electroporation.
  • Cross-strain protective antibodies, a critical step in the development of a universal influenza vaccine:
    • SynCon® avian influenza vaccine generated HAI titers in human subjects against six different, unmatched strains of H5N1. The vaccine candidate generated strong binding antibodies in 96% of subjects and strong CTL responses to at least one of the vaccine components in 72% of subjects.
    • In preclinical animal studies, our H1N1 influenza synthetic vaccine demonstrated protection against unmatched 1918 pandemic H1N1 and 2009 swine flu strains.
    • Synthetic vaccines for influenza Type A H3N2 and Type B achieved protective antibody responses against multiple unmatched strains in immunized animals, further validating potential to create a universal influenza vaccine.
  • Complete clearance of the virus in 83% of subjects (measured up to six months) of our collaborator ChronTech’s hepatitis C virus vaccine , delivered using Inovio’s electroporation delivery system, in conjunction with conventional standard of care (interferon + ribavirin) reported in Phase I clinical study. Conventional standard of care alone achieves clearance of 40% - 50%.
Back to Top